FORM 4	ŀ
--------	---

-
Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-028 Estimated average burden 0.5 hours per response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print of Type Responses)											
1. Name and Address of Reporting Person Benaim Ely	2. Issuer Name and Ticker or Trading Symbol REXAHN PHARMACEUTICALS, INC. [RNN]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) C/O REXAHN PHARMACEUTICA INC., 15245 SHADY GROVE ROA 455	3. Date of Earliest Transaction (Month/Day/Year) 02/28/2019						X Officer (give title below) Other (specify below) Chief Medical Officer				
(Street) ROCKVILLE, MD 20850		4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City) (State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
(Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution Date, if	Code (A) or Disposed of (Instr. 8) (D)		5. Amount of Securities 6. 7. Nat Beneficially Owned Following Ownership of Indi Reported Transaction(s) Form: Beneficially (Instr. 3 and 4) Direct (D) Owner						
			Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	(Instr. 4)	
Common Stock	02/28/2019		М		2,375	А	\$ 0	4,750	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)													
of 2. 3. Transaction	a 3A. Deemed 4	4.	5	5. N	umber	6. Date Exer	cisable	7. Title and		8. Price of	9. Number of	10.	11. Nature
tive Conversion Date	Execution Date, if T	Transactic	on c	of and Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect		
y or Exercise (Month/Day/Yea	(ear) any C	Code	Ι	Deri	vative	(Month/Day	/Year)	Underlying		Security	Securities	Form of	Beneficial
3) Price of	(Month/Day/Year) (I	(Instr. 8)			irities			Securities		(Instr. 5)			Ownership
Derivative					uired			(Instr. 3 and	14)			Security:	(Instr. 4)
Security				A) (Direct (D)	
					osed						1	or Indirect	
				of (I							Transaction(s)	· · /	
					r. 3, 4,						(Instr. 4)	(Instr. 4)	
	_		a	ind :	3)		1		1				
									Amount				
						Date	Expiration		or				
						Exercisable	Date						
		Cada	v (•	(D)								
		Code	v (A)	(D)	-			Shares				
cted								Common					
(1) 02/28/2019	9	М			2,375	<u>(2)</u>	<u>(2)</u>		2,375	\$ 0	4,750	D	
								STOCK					
			V ((A)	(D)	Exercisable			Number of Shares		4,750	D	

Reporting Owners

Reporting Owner Name / Address	Relationships							
		10% Owner	Officer	Other				
Benaim Ely C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850			Chief Medical Officer					

Signatures

/s/ Douglas J. Swirsky, as attorney-in-fact for Ely Benaim	03/01/2019	
-**Signature of Reporting Person	Date	

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock.

(2) On January 20, 2017, the reporting person was granted 9,500 RSUs, of which 2,375 vested on February 28, 2018 and 2,375 vested on February 28, 2019. The remaining RSUs will vest in two equal annual installments on the last business day in February beginning February 28, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.